Advisory Board January 23, 2025

According to a new study published in Nature Medicine, GLP-1 drugs were associated with a decreased risk of 42 health conditions, including Alzheimer’s disease. However, the drugs were also associated with an increased risk of 19 other health conditions.

What the future of weight management drugs could hold

Study details and key findings

For the study, researchers analyzed the health records of over 2 million patients with diabetes in the Veterans Affairs database. Among the patients, 215,970 were taking GLP-1 drugs while the remainder received other diabetes drugs and usual care. Between October 2017 and December 2023, the researchers tracked patients’ outcomes for 175 different health conditions.

Overall, the researchers found that patients who took GLP-1 drugs had lower risks...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
Pharma Pulse 1/23/25: Technology’s Role in Trial Design Optimization, Trump's Impact on Medicare Drug Price Negotiations & more
Healthcare and Life Sciences: Key Insights and Considerations for Stakeholders in 2025
BridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors
States consider high costs, possible savings of covering weight-loss drugs for their workers
Closing the women’s health gap: Biopharma’s untapped opportunity

Share This Article